San Antonio biotech acquires U.K. wound-care company

Acelity LP President and CEO Andrew Eckert says the company's acquisition of England's Crawford Healthcare ...

Kiromic founder says Houston biotech’s move to SA nearly a done deal

Houston-based immunotherapy company Kiromic is expected this month to approve moving its headquarters ...


4th Annual SURF 2018

What: San Antonio Military Health System and Universities ResearchForum When: Thursday, June ...

SwRI 2018 International Human Performance Summit

June 30-July 1, 2018 The Summit will be hosted by Southwest Research Institute as part of its ongoing ...
San Antonio’s EO2 Concepts advancing new technology that could impact millions of diabetics
June 2, 2015

Courtesy of EO2 Concepts

By W. Scott Bailey, San Antonio Business Journal

A significant number of San Antonians are dealing with diabetes, so it's only fitting that an Alamo City company is advancing technology which could prove critical in helping treat diabetic wounds. EO2 Concepts has interim results from a new study which indicate that the company's TransCu O2 device provides more effective and less expensive treatment for millions of diabetics suffering from chronic wounds.

The TransCu O2 tissue oxygenation device is portable and allows for constant treatment without limiting patients' mobility. The device provides a continuous supply of low-flow pure oxygen which can help treat a variety of lower-limb wounds, including venous leg ulcers, diabetic foot ulcers and pressure ulcers.

Preliminary results from the new study suggest encouraging trends for patients receiving Continuous Diffusion of Oxygen, or CDO, therapy for such chronic wounds. Roughly 53 percent of patients receiving CDO therapy via the TransCu 02 device experienced complete wound closure in 12 weeks, an improvement over published results from other would-be therapies, according to EO2 Concepts officials.

Mark Niederauer, chief operating officer for EO2 Concepts, said CDO therapy is a "very promising therapeutic approach" that company officials believe could "transform the current standard of care" for millions of diabetics who struggle with chronic wounds. He said the therapy was found to have results equivalent or superior to other advanced treatments, yet is easier to apply and less costly.

While oxygen-based therapies have been proven to be effective in treating chronic wounds, the therapeutic approach to allow for 24-hour delivery of diffused oxygen is relatively new, according to officials with EO2 Concepts. Niederauer said the private company is proceeding with additional studies officials expect will further validate the efficacy of their technology.


Stay informed. Subscribe to BioMed SA news alerts.